Insights - At a medical meeting this week Alnylam Pharmaceuticals (ALNY) reported six-month data from an ongoing study of patisiran (ALN-TTR02) in the rare disorder TTR-mediated amyloidosis (ATTR) in patients with … Continue Reading
Read NowInsights - Shares of Exact Sciences (EXAS) ripped higher on Friday with news that reimbursement for Cologuard should come in at the high end of analyst and investor … Continue Reading
Read NowInsights - Endo Health (ENDP) and Auxilium Pharmaceuticals (AUXL) finally came to terms in ongoing buyout negotiations, with ENDP handing over $2.6 billion ($33.25 per share) in … Continue Reading
Read NowInsights - Actavis (ACT) continued its acquisition spree on Mondau morning with the purchase of Durata Therapeutics (DRTX) in a deal valued at $675 million. The Dublin based … Continue Reading
Read NowInsights - Sunesis Pharmaceuticals (SNSS) announced Monday much-anticipated results from the pivotal Phase 3 VALOR trial, a randomized, double-blind, placebo-controlled trial of vosaroxin (trademark Qinprezo) and cytarabine in … Continue Reading
Read NowInsights - Salix Pharmaceuticals Ltd. (SLXP) announced the end of a $2.7 billion merger agreement with Cosmo Pharmaceuticals SpA (COPN), citing tougher U.S rules for overseas inversions. … Continue Reading
Read NowInsights - Esperion Therapeutics Inc (ESPR) hit a home run with top-line results from ETC-1002-008, a 12-week Phase 2b study that is one of the largest ever … Continue Reading
Read Now
